US Patent

US10329260 — Human plasma kallikrein inhibitors

Composition of Matter · Assigned to Biocryst Pharmaceuticals Inc · Expires 2035-03-09 · 9y remaining

Vulnerability score 4/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects compounds that inhibit plasma kallikrein, as well as pharmaceutical compositions and methods using these compounds.

USPTO Abstract

Disclosed are compounds of formula I as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also disclosed are pharmaceutical compositions comprising at least one such compound, and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.

Drugs covered by this patent

Patent Metadata

Patent number
US10329260
Jurisdiction
US
Classification
Composition of Matter
Expires
2035-03-09
Drug substance claim
Yes
Drug product claim
No
Assignee
Biocryst Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.